LIXTE Biotechnology Holdings, a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, has appointed Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun previously facilitated LIXTE's November 2025 acquisition of Liora's assets and brings more than 20 years of healthcare operational and strategic advisory experience to the role.
Braun will lead advancement of Liora's LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management stated the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care. The move represents a significant step in LIXTE's expansion into advanced cancer treatment technologies beyond its pharmaceutical development programs.
LIXTE Biotechnology Holdings is primarily known for its clinical-stage pharmaceutical work focused on new targets for cancer drug development. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
The company's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality that is advancing a new treatment paradigm. LIXTE's approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The appointment of Braun to lead the European subsidiary represents a strategic integration of LIXTE's pharmaceutical expertise with advanced medical technology. Proton therapy represents a growing segment of cancer treatment that offers potential advantages over traditional radiation therapy by more precisely targeting tumors while sparing surrounding healthy tissue. The LiGHT System's electronically controlled platform could represent an advancement in this field, potentially making proton therapy more accessible and effective.
For investors and industry observers, this appointment signals LIXTE's commitment to building a diversified oncology portfolio that includes both pharmaceutical and medical technology approaches to cancer treatment. The move toward a recurring revenue model in radiotherapy suggests a long-term strategy to establish sustainable revenue streams alongside its drug development pipeline. The full press release detailing this appointment is available at https://ibn.fm/9kbfE, while comprehensive disclaimers and forward-looking statement information can be found at http://IBN.fm/Disclaimer.
The development comes as the global cancer therapy market continues to expand, with increasing demand for more precise and effective treatment options. Proton therapy systems represent a significant technological advancement in radiation oncology, and LIXTE's investment in this area through its European subsidiary positions the company to potentially capture market share in this specialized segment. The appointment of an experienced healthcare executive like Braun suggests the company is serious about commercializing this technology alongside its pharmaceutical developments.
